Modality
mRNA
MOA
IL-13i
Target
IL-17A
Pathway
T-cell
OCDHeart Failure
Development Pipeline
Preclinical
~Oct 2012
→ ~Jan 2014
Phase 1
~Apr 2014
→ ~Jul 2015
Phase 2
~Oct 2015
→ ~Jan 2017
Phase 3
Apr 2017
→ Nov 2029
Phase 3Current
NCT04836435
1,321 pts·OCD
2024-03→2025-10·Terminated
NCT07056568
1,539 pts·OCD
2017-04→2027-08·Not yet recruiting
NCT07882045
2,888 pts·OCD
2018-07→2029-11·Completed
+1 more trial
7,644 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-10-046mo agoPh3 Readout· OCD
2027-08-281.4y awayPh3 Readout· OCD
2029-07-203.3y awayPh3 Readout· OCD
2029-11-033.6y awayPh3 Readout· OCD
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P3
Not yet…
P3
Complet…
P3
Termina…
P3
Not yet…
Catalysts
Ph3 Readout
2025-10-04 · 6mo ago
OCD
Ph3 Readout
2027-08-28 · 1.4y away
OCD
Ph3 Readout
2029-07-20 · 3.3y away
OCD
Ph3 Readout
2029-11-03 · 3.6y away
OCD
CompletedTerminatedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04836435 | Phase 3 | OCD | Terminated | 1321 | SRI-4 |
| NCT07056568 | Phase 3 | OCD | Not yet recr... | 1539 | SeizFreq |
| NCT07882045 | Phase 3 | OCD | Completed | 2888 | PFS |
| NCT07732071 | Phase 3 | OCD | Not yet recr... | 1896 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxaderotide | Johnson & Johnson | NDA/BLA | PI3Kα | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| AMG-1919 | Amgen | Phase 2/3 | CDK2 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 |